A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability and
pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy
adults.
Participants will be administered a single intravenous dose of NoNO-42 or placebo.
Participants will be confined for 24 hours post dose with a follow-up visit at Day 4 and Day
28.